Probiotics combined with Budesonide and Ipratropium bromide for chronic obstructive pulmonary disease: A retrospective analysis.

To explore the effect of probiotics combined with budesonide and ipratropium bromide in the treatment of chronic obstructive pulmonary disease (COPD) on lung function and gut microbiota. This was a retrospective study of prospectively collected clinical data of 118 patients with COPD admitted to our hospital between January 2020 and December 2022. According to the treatment records, 59 patients received budesonide and irpratropium bromide (control group), and 59 patients received probiotics combined with budesonide and irpratropium bromide (observation group). The lung function, inflammatory factor levels, airway remodeling, and gut microbiota before and after treatment were compared between the 2 groups. After treatment, FVC, MMEF, PEF, and FEV1 in the 2 groups were higher than before treatment, and the values in the observation group were higher than those in the control group (P < .05). After treatment, the serum levels of TNF-α, IL-6, and PCT in the 2 groups were lower than before treatment, and the levels in the observation group were lower than those in the control group (P < .05). After treatment, the levels of serum MMP-9, VEGF, basic fibroblast growth factor, and NGF in the 2 groups were lower than before treatment, and the levels in the observation group were lower than those in the control group (P < .05). After treatment, the levels of lactobacilli and bifidobacteria in the 2 groups increased compared to those before treatment, and the observation group had a higher level, while the levels of Enterobacteriaceae and Enterococcus were lower in the observation group than those before treatment (P < .05). Based on budesonide and irpratropium bromide, probiotic treatment of COPD is more conducive to reducing the degree of inflammatory reactions, inhibiting airway remodeling, regulating the level of gut microbiota, and promoting the recovery of lung function.

Application value and safety of NIPPV combined with routine clearance in the treatment of stroke-associated pneumonia in elderly patients.

OBJECTIVE: To investigate the application value and safety of NIPPV (noninvasive positive pressure ventilation) combined with routine clearance in elderly patients with stroke-associated pneumonia (SAP). METHODS: Altogether 88 elderly SAP patients treated in our hospital from January 2021 to January 2022 were retrospectively evaluated. Among them, 48 cases treated with NIPPV and routine clearance were regarded as an experimental group (EG), and 40 with routine clearance alone were enrolled to a control group (CG). The sputum clearance rate and CPIS score were compared. The safety of NIPPV was evaluated. The clearance treatment cost, hospitalization time and expenses, and the changes of inflammatory factors (IL-6, TNF-α, C-reactive protein (CRP)) were compared before and after treatment. The efficacy of airway clearance after treatment and the risk factors affecting the severity of infection was assessed. RESULTS: The sputum clearance rate in the EG was higher than that in the CG (P < 0.05). After treatment, the CPIS score of EG was lower (P < 0.05). The hospitalization time and expenses of CG were higher. After treatment, the serum inflammatory factors in CG were higher (P < 0.05), while the clinical efficacy of EG was higher (P < 0.05). Treatment plan, course of disease and diabetes are risk factors for postoperative infection. CONCLUSION: NIPPV combined with routine clearance is effective for elderly SAP patients, which can shorten the hospitalization time and reduce the expenses.